Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 41

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 41
---
 the prospectus supplement in electronic format, the information on the Placement Agent’s website and any information contained in any other website maintained by the Placement Agent is not part of the prospectus supplement or the registration statement of which this prospectus supplement forms a part, has not been approved and/or endorsed by us or the Placement Agent in its capacity as Placement Agent and should not be relied upon by investors.

The foregoing does not purport to be a complete statement of the terms and conditions of the Engagement Agreement and the securities purchase agreement. A copy of the Engagement Agreement and the securities purchase agreement with the purchasers will be included as an exhibit to our Current Report on Form 8-K to be filed with the SEC and incorporated by reference into the registration statement of which this prospectus supplement and the accompanying prospectus form a part. See “ Where You Can Find More Information” and “ Information We Incorporate By Reference.”

Tail Compensation

We have granted the Placement Agent a right of first refusal for a period of twelve-months following the closing of this offering to act as our sole book-running manager, sole underwriter or sole placement agent for any further capital raising transactions undertaken by us.

We also have granted Placement Agent a tail cash fee equal to 7.5% of the gross proceeds and warrants to purchase shares of common stock equal to 7.5% of the aggregate number of shares of common stock sold in any offering, within twelve months following the termination of the engagement letter agreement, to investors whom the Placement Agent contacted or introduced to us directly or indirectly in connection with this offering.

In addition, we have agreed to pay Placement Agent the following compensation in connection with any future exercise of the Private Placement Warrants issued in the concurrent private placement: (i) a cash fee equal to 7.5% of the aggregate gross exercise price paid in cash with respect to the exercise of the Private Placement Warrants; and (ii) a management fee equal to 1.0% of the aggregate gross exercise price paid in cash with respect to the exercise of the Private Placement Warrants and issue to the Private Placement (or its designees) warrants to purchase shares of our common stock representing 7.5% of the shares of common stock underlying the Private Placement Warrants that have been exercised.

<div align='center'>S-25</div>

From the date hereof until five days after the after the closing of this offering, subject to certain exceptions, we may not issue, enter into any agreement to issue or announce the issuance or proposed issuance of any